Abstract

INSEPTEMBER1994, the Food and Drug Administration (FDA) circulated a medical bulletin informing physicians and other health care professionals that several reports (to the FDA) of serious radiation injuries to skin had resulted from prolonged fluoroscopic imaging during interventional therapeutic procedures. 1 Long exposure times, high dose rates, and operators' lack of awareness that the doses used exceeded the threshold for radiodermatitis all were implicated. Several procedures involving fluoroscopic exposure times that were potentially prolonged, repetitious, or both were listed, including percutaneous transluminal angioplasty, radiofrequency cardiac catheter ablation, vascular embolization, stent and filter placement, thrombolytic and fibrinolytic procedures, and percutaneous transhepatic cholangiography for portal decompression. It was emphasized that for single short-term exposures, the threshold dose was about 3 Gy (1 Gy is equivalent to 100 rad) for temporary epilation, 6 to 8 Gy for erythema (at 200 kV), and 15 Gy or higher for moist desquamation,

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.